Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Cancer Res
    April 2024
  1. ZHENG SM, Feng YC, Zhu Q, Li RQ, et al
    MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer.
    Cancer Res. 2024 Apr 9:OF1-OF15. doi: 10.1158/0008-5472.CAN-23-3046.
    >> Share

    March 2024
  2. ZHANG M, Zhou K, Wang Z, Liu T, et al
    A subpopulation of luminal progenitors secretes pleiotrophin to promote angiogenesis and metastasis in inflammatory breast cancer.
    Cancer Res. 2024 Mar 20. doi: 10.1158/0008-5472.CAN-23-2640.
    >> Share

  3. QIU Y, Wang X, Sun Y, Jin T, et al
    ACSL4-mediated membrane phospholipid remodeling induces integrin beta1 activation to facilitate triple-negative breast cancer metastasis.
    Cancer Res. 2024 Mar 12. doi: 10.1158/0008-5472.CAN-23-2491.
    >> Share

    February 2024
  4. YAMAMOTO T, Hayashida T, Masugi Y, Oshikawa K, et al
    PRMT1 sustains de novo fatty acid synthesis by methylating PHGDH to drive chemoresistance in triple-negative breast cancer.
    Cancer Res. 2024 Feb 22. doi: 10.1158/0008-5472.CAN-23-2266.
    >> Share

  5. YAN L, Wu M, Wang T, Yuan H, et al
    Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming that Drives Immune Evasion.
    Cancer Res. 2024 Feb 9. doi: 10.1158/0008-5472.CAN-23-2390.
    >> Share

  6. BERNARD MJ, Goldstein AS
    A metabolic-epigenetic mechanism directs cell fate and therapeutic sensitivity in breast cancer.
    Cancer Res. 2024 Feb 8. doi: 10.1158/0008-5472.CAN-24-0460.
    >> Share

  7. GEDIK ME, Saatci O, Oberholtzer N, Uner M, et al
    Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer.
    Cancer Res. 2024 Feb 6. doi: 10.1158/0008-5472.CAN-23-2812.
    >> Share

    January 2024
  8. MARQUEZ-PALENCIA M, Reza Herrera L, Parida PK, Ghosh S, et al
    AXL/WRNIP1 mediates replication stress response and promotes therapy resistance and metachronous metastasis in HER2+ breast cancer.
    Cancer Res. 2024 Jan 8. doi: 10.1158/0008-5472.CAN-23-1459.
    >> Share

  9. SOOSAINATHAN A, Iravani M, El-Botty R, Alexander J, et al
    Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.
    Cancer Res. 2024;84:17-25.
    >> Share

    December 2023
  10. KIM S, Oh J, Park C, Kim M, et al
    FAM3C in cancer-associated adipocytes promotes breast cancer cell survival and metastasis.
    Cancer Res. 2023 Dec 20. doi: 10.1158/0008-5472.CAN-23-1641.
    >> Share

  11. LIN P, Lourenco C, Cruickshank J, Palomero L, et al
    Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality.
    Cancer Res. 2023;83:4015-4029.
    >> Share

  12. COMPTON ZT, Mallo D, Maley CC
    Stronger Together: Cancer Clones Cooperate to Alleviate Growth Barriers in Critical Cancer Progression Transitions.
    Cancer Res. 2023;83:4013-4014.
    >> Share

  13. MICHAUD DE, Guerriero JL
    Myeloid cells pave the metastatic road in breast cancer.
    Cancer Res. 2023 Dec 6. doi: 10.1158/0008-5472.CAN-23-3803.
    >> Share

  14. FAN H, Xu Z, Yao K, Zheng B, et al
    Osteoclast-Cancer Cell Metabolic Crosstalk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer.
    Cancer Res. 2023 Dec 1. doi: 10.1158/0008-5472.CAN-23-1443.
    >> Share

    November 2023
  15. WALL SW, Echeverria GV
    Avoiding Extinction: Cancer-Associated Fibroblasts Help Triple-Negative Breast Cancer Outrun Chemotherapy.
    Cancer Res. 2023;83:3667-3669.
    >> Share

  16. XU Y, Li X, Zhang S, Tang M, et al
    CircMMP2(6,7) cooperates with beta-catenin and PRMT5 to disrupt bone homeostasis and promote breast cancer bone metastasis.
    Cancer Res. 2023 Nov 14. doi: 10.1158/0008-5472.CAN-23-1899.
    >> Share

    October 2023
  17. AHN S, Park JH, Grimm SL, Piyarathna DWB, et al
    Metabolomic rewiring promotes endocrine therapy resistance in breast cancer.
    Cancer Res. 2023 Oct 31. doi: 10.1158/0008-5472.CAN-23-0184.
    >> Share

  18. JACOBS C, Shah S, Lu WC, Ray H, et al
    HSF1 inhibits antitumor immune activity in breast cancer by suppressing CCL5 to block CD8+ T cell recruitment.
    Cancer Res. 2023 Oct 27. doi: 10.1158/0008-5472.CAN-23-0902.
    >> Share

  19. MIROSHNYCHENKO D, Miti T, Kumar P, Miller A, et al
    Stroma-mediated breast cancer cell proliferation indirectly drives chemoresistance by accelerating tumor recovery between chemotherapy cycles.
    Cancer Res. 2023 Oct 4. doi: 10.1158/0008-5472.CAN-23-0398.
    >> Share

  20. WU J, Subbiah V
    RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond.
    Cancer Res. 2023;83:3159-3161.
    >> Share

  21. WINGATE HF, Keyomarsi K
    Distinct Mechanisms of Resistance to CDK4/6 Inhibitors Require Specific Subsequent Treatment Strategies: One Size Does Not Fit All.
    Cancer Res. 2023;83:3165-3167.
    >> Share

  22. NAVARRO-YEPES J, Kettner NM, Rao X, Bishop CS, et al
    Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.
    Cancer Res. 2023;83:3264-3283.
    >> Share

    September 2023
  23. LAWSON M, Cureton N, Ros S, Cheraghchi-Bashi-Astaneh A, et al
    The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance.
    Cancer Res. 2023 Sep 19. doi: 10.1158/0008-5472.CAN-23-0694.
    >> Share

  24. MUKHERJEE D, Previs RA, Haines C, Al Abo M, et al
    Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis.
    Cancer Res. 2023;83:2889-2907.
    >> Share

    August 2023
  25. COHEN N, Mundhe D, Deasy SK, Adler O, et al
    Breast cancer-secreted factors promote lung metastasis by signaling systemically to induce a fibrotic pre-metastatic niche.
    Cancer Res. 2023 Aug 7:CAN-22-3707. doi: 10.1158/0008-5472.CAN-22-3707.
    >> Share

  26. ZHU YY, Song L, Zhang YQ, Liu WL, et al
    Development of a rare earth nanoprobe enables in vivo real-time detection of sentinel lymph node metastasis of breast cancer using NIR-IIb imaging.
    Cancer Res. 2023 Aug 4:CAN-22-3432. doi: 10.1158/0008-5472.CAN-22-3432.
    >> Share

  27. MATHUR D, Liao C, Lin W, La Ferlita A, et al
    The ratio of key metabolic transcripts is a predictive biomarker of breast cancer metastasis to the lung.
    Cancer Res. 2023 Aug 1:CAN-23-0153. doi: 10.1158/0008-5472.CAN-23-0153.
    >> Share

  28. SCHMIT SL, Purrington K, Figueiredo JC
    Efforts to Grow Genomic Research in Ancestrally Diverse and Admixed Populations.
    Cancer Res. 2023;83:2443-2444.
    >> Share

  29. HU C, Nagaraj AB, Shimelis H, Montalban G, et al
    Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.
    Cancer Res. 2023;83:2557-2571.
    >> Share

  30. SHU X, Li J, Chan UI, Su SM, et al
    BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance.
    Cancer Res. 2023;83:2614-2633.
    >> Share

  31. DING YC, Song H, Adamson AW, Schmolze D, et al
    Profiling the Somatic Mutational Landscape of Breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics.
    Cancer Res. 2023;83:2600-2613.
    >> Share

    July 2023
  32. AMAYA RAMIREZ CC, Loayza-Puch F
    Breast Cancer Metastatic Progression Requires mRNA Posttranscriptional Suppression.
    Cancer Res. 2023 Jul 19:OF1-OF2. doi: 10.1158/0008-5472.CAN-23-1729.
    >> Share

  33. WANG Z, Zhang N, Zhang M, Jiang Y, et al
    GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner.
    Cancer Res. 2023 Jul 18:CAN-22-3471. doi: 10.1158/0008-5472.CAN-22-3471.
    >> Share

  34. YU S, Wang Y, Gong X, Fan Z, et al
    LncRNA AGPG confers endocrine resistance in breast cancer by promoting E2F1 activity.
    Cancer Res. 2023 Jul 18:CAN-23-0015. doi: 10.1158/0008-5472.CAN-23-0015.
    >> Share

  35. HERMIDA-PRADO F, Xie Y, Sherman S, Nagy Z, et al
    Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer.
    Cancer Res. 2023 Jul 14:CAN-23-1711. doi: 10.1158/0008-5472.CAN-23-1711.
    >> Share

  36. ACETO N, Gvozdenovic A
    Metastasis Unleashed: Hyposialylation Empowers Chemo-Evasive Circulating Tumor Cell Clusters in Breast Cancer.
    Cancer Res. 2023 Jul 7:CAN-23-1978. doi: 10.1158/0008-5472.CAN-23-1978.
    >> Share

  37. MARIN A, Mamun AA, Patel H, Akamatsu H, et al
    Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in breast cancer.
    Cancer Res. 2023 Jul 5:CAN-22-3617. doi: 10.1158/0008-5472.CAN-22-3617.
    >> Share

  38. NULL JL, Kim DJ, McCann JV, Pramoonjago P, et al
    Periostin+ Stromal Cells Guide Lymphovascular Invasion by Cancer Cells.
    Cancer Res. 2023;83:2105-2122.
    >> Share

  39. KA NL, Park MK, Kim SS, Jeon Y, et al
    NR1D1 stimulates antitumor immune responses in breast cancer by activating cGAS-STING signaling.
    Cancer Res. 2023 Jul 3:CAN-23-0329. doi: 10.1158/0008-5472.CAN-23-0329.
    >> Share

    June 2023
  40. FATTORI S, Le Roy A, Houacine J, Robert L, et al
    CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer.
    Cancer Res. 2023 Jun 28:CAN-23-0613. doi: 10.1158/0008-5472.CAN-23-0613.
    >> Share

  41. LI B, Qi F, Zhu F, Lu Z, et al
    Nanoparticle-based combination therapy enhances fulvestrant efficacy and overcomes tumor resistance in ER-positive breast cancer.
    Cancer Res. 2023 Jun 16:CAN-22-3559. doi: 10.1158/0008-5472.CAN-22-3559.
    >> Share

  42. JAILKHANI N, Clauser KR, Mak HH, Rickelt S, et al
    Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases.
    Cancer Res. 2023;83:2052-2065.
    >> Share

  43. LI Z, Li T, Yates ME, Wu Y, et al
    The EstroGene database reveals diverse temporal, context-dependent, and bidirectional estrogen receptor regulomes in breast cancer.
    Cancer Res. 2023 Jun 5:CAN-23-0539. doi: 10.1158/0008-5472.CAN-23-0539.
    >> Share

  44. CHENG X, Sun Y, Highkin M, Vemalapally N, et al
    Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 -Cyclin D1 axis driving tumorigenesis and drug resistance.
    Cancer Res. 2023 Jun 5:CAN-22-3558. doi: 10.1158/0008-5472.CAN-22-3558.
    >> Share

    May 2023
  45. RODA N, Cossa A, Hillje R, Tirelli A, et al
    A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer.
    Cancer Res. 2023 May 3:CAN-22-2717. doi: 10.1158/0008-5472.CAN-22-2717.
    >> Share

  46. PENG WT, Jin X, Xu XE, Yang YS, et al
    Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer.
    Cancer Res. 2023 May 2:OF1-OF14. doi: 10.1158/0008-5472.CAN-22-2143.
    >> Share

    April 2023
  47. GOU X, Kim BJ, Anurag M, Lei JT, et al
    Kinome reprogramming is a targetable vulnerability in ESR1 fusion-driven breast cancer.
    Cancer Res. 2023 Apr 18:CAN-22-3484. doi: 10.1158/0008-5472.CAN-22-3484.
    >> Share

  48. LU XX, Yang WX, Pei YC, Luo H, et al
    An in vivo CRISPR screen identifies that SNRPC promotes triple-negative breast cancer progression.
    Cancer Res. 2023 Apr 14:CAN-22-0536. doi: 10.1158/0008-5472.CAN-22-0536.
    >> Share

  49. KHATPE AS, Dirks R, Bhat-Nakshatri P, Mang H, et al
    TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer.
    Cancer Res. 2023;83:1345-1360.
    >> Share

  50. SUN Z, Jiang Q, Gao B, Zhang X, et al
    AKT Blocks SIK1-Mediated Repression of STAT3 to Promote Breast Tumorigenesis.
    Cancer Res. 2023;83:1264-1279.
    >> Share

    March 2023
  51. SALVADOR F, Martin A, Lopez-Menendez C, Moreno-Bueno G, et al
    Correction: Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer.
    Cancer Res. 2023;83:974.
    >> Share

    February 2023
  52. MALIK N, Kim YI, Yan H, Tseng YC, et al
    Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer.
    Cancer Res. 2023 Feb 14:CAN-22-2525. doi: 10.1158/0008-5472.CAN-22-2525.
    >> Share

    January 2023
  53. ANSTINE LJ, Majmudar PR, Aponte A, Singh S, et al
    TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis.
    Cancer Res. 2023 Jan 25:CAN-22-3133. doi: 10.1158/0008-5472.CAN-22-3133.
    >> Share

  54. DAS C, Adhikari S, Bhattacharya A, Chakraborty S, et al
    Epigenetic-Metabolic Interplay in the DNA Damage Response and Therapeutic Resistance of Breast Cancer.
    Cancer Res. 2023 Jan 18:CAN-22-3015. doi: 10.1158/0008-5472.CAN-22-3015.
    >> Share

    December 2022
  55. WEIGEL C, Maczis MA, Palladino END, Green CD, et al
    Sphingosine kinase 2 in stromal fibroblasts creates a hospitable tumor microenvironment in breast cancer.
    Cancer Res. 2022 Dec 21:CAN-22-1638. doi: 10.1158/0008-5472.CAN-22-1638.
    >> Share

  56. LIAO L, Zhang YL, Deng L, Chen C, et al
    Protein phosphatase 1 subunit PPP1R14B stabilizes STMN1 to promote progression and paclitaxel resistance in triple-negative breast cancer.
    Cancer Res. 2022 Dec 9:CAN-22-2709. doi: 10.1158/0008-5472.CAN-22-2709.
    >> Share

  57. WEI L, Gao H, Yu J, Zhang H, et al
    Pharmacological targeting of androgen receptor elicits context-specific effects in estrogen receptor-positive breast cancer.
    Cancer Res. 2022 Dec 5:CAN-22-1016. doi: 10.1158/0008-5472.CAN-22-1016.
    >> Share

    November 2022
  58. STEVENS LE, Peluffo G, Qiu X, Temko D, et al
    JAK-STAT signaling in inflammatory breast cancer enables chemotherapy-resistant cell states.
    Cancer Res. 2022 Nov 21:CAN-22-0423. doi: 10.1158/0008-5472.CAN-22-0423.
    >> Share

  59. WANG F, Moon W, Letsou W, Sapkota Y, et al
    Genome-wide Analysis of Rare Haplotypes Associated with Breast Cancer Risk.
    Cancer Res. 2022 Nov 10. pii: 710536. doi: 10.1158/0008-5472.CAN-22-1888.
    >> Share

  60. GONG P, Chin SL, Allen WM, Ballal H, et al
    Quantitative Micro-Elastography Enables In Vivo Detection of Residual Cancer in the Surgical Cavity during Breast-Conserving Surgery.
    Cancer Res. 2022;82:4093-4104.
    >> Share

  61. PERRONE M, Chiodoni C, Lecchi M, Botti L, et al
    ATF3 reprograms the bone marrow niche in response to early breast cancer transformation.
    Cancer Res. 2022 Nov 1. pii: 710151. doi: 10.1158/0008-5472.CAN-22-0651.
    >> Share

    October 2022
  62. HALPERIN C, Hey J, Weichenhan D, Stein Y, et al
    Global DNA Methylation Analysis of Cancer-Associated Fibroblasts Reveals Extensive Epigenetic Rewiring Linked with RUNX1 Upregulation in Breast Cancer Stroma.
    Cancer Res. 2022 Oct 26:OF1-OF14. doi: 10.1158/0008-5472.CAN-22-0209.
    >> Share

  63. BASSIOUNI R, Idowu MO, Gibbs LD, Robila V, et al
    Spatial transcriptomic analysis of a diverse patient cohort reveals a conserved architecture in triple-negative breast cancer.
    Cancer Res. 2022 Oct 25. pii: 710045. doi: 10.1158/0008-5472.CAN-22-2682.
    >> Share

  64. HARGROVE-WILEY E, Fingleton B
    Sex hormones in breast cancer immunity.
    Cancer Res. 2022 Oct 24. pii: 709945. doi: 10.1158/0008-5472.CAN-22-1829.
    >> Share

  65. TARANTINO P, Tolaney SM
    The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors.
    Cancer Res. 2022;82:3659-3661.
    >> Share

  66. BLAWSKI R, Toska E
    A Unique FOXA1-Associated Chromatin State Dictates Therapeutic Resistance in Lobular Breast Cancer.
    Cancer Res. 2022;82:3668-3670.
    >> Share

  67. DURO-SANCHEZ S, Nadal-Serrano M, Lalinde-Gutierrez M, Arenas EJ, et al
    Therapy-induced senescence enhances the efficacy of HER2-targeted antibody-drug conjugates in breast cancer.
    Cancer Res. 2022 Oct 12. pii: 709715. doi: 10.1158/0008-5472.CAN-22-0787.
    >> Share

  68. HONG J, Lee JH, Zhang Z, Wu Y, et al
    PRC2-mediated epigenetic suppression of type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer.
    Cancer Res. 2022 Oct 12. pii: 709714. doi: 10.1158/0008-5472.CAN-22-0736.
    >> Share

  69. ELKHOLI IE, Lalonde A, Park M, Cote JF, et al
    Breast Cancer Metastatic Dormancy and Relapse: An enigma of microenvironment(s).
    Cancer Res. 2022 Oct 10. pii: 709673. doi: 10.1158/0008-5472.CAN-22-1902.
    >> Share

    September 2022
  70. TOKURA M, Nakayama J, Prieto-Vila M, Shiino S, et al
    Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ.
    Cancer Res. 2022;82:3236-3248.
    >> Share

  71. LIU H, Lyu H, Jiang G, Chen D, et al
    ALKBH5-mediated m6A demethylation of GLUT4 mRNA promotes glycolysis and resistance to HER2-targeted therapy in breast cancer.
    Cancer Res. 2022 Sep 7. pii: 709106. doi: 10.1158/0008-5472.CAN-22-0800.
    >> Share

    August 2022
  72. FATTORI S, Roux H, Connen E, Robert L, et al
    Therapeutic targeting of tumor-infiltrating regulatory T cells in breast cancer.
    Cancer Res. 2022 Aug 30. pii: 708918. doi: 10.1158/0008-5472.CAN-22-0654.
    >> Share

  73. GUO Q, Wang H, Duan J, Luo W, et al
    An alternatively spliced p62 isoform confers resistance to chemotherapy in breast cancer.
    Cancer Res. 2022 Aug 29. pii: 708925. doi: 10.1158/0008-5472.CAN-22-0909.
    >> Share

  74. NANDI A, Debnath R, Nayak A, To TKJ, et al
    Dll1-mediated Notch signaling drives tumor cell crosstalk with cancer associated fibroblasts to promote radioresistance in breast cancer.
    Cancer Res. 2022 Aug 24. pii: 708708. doi: 10.1158/0008-5472.CAN-21-1225.
    >> Share

  75. ZENG E, He W, Sjolander A, Bergqvist J, et al
    Determinants and effectiveness of extending the duration of adjuvant hormone therapy beyond 5 years in breast cancer patients.
    Cancer Res. 2022 Aug 18. pii: 708038. doi: 10.1158/0008-5472.CAN-22-0900.
    >> Share

  76. MOASSER MM
    Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions.
    Cancer Res. 2022;82:2811-2820.
    >> Share

  77. ALTWEGG KA, Viswanadhapalli S, Mann M, Chakravarty D, et al
    A first-in-class inhibitor of ER coregulator PELP1 targets ER+ breast cancer.
    Cancer Res. 2022 Aug 11. pii: 707658. doi: 10.1158/0008-5472.CAN-22-0698.
    >> Share

  78. NARDONE A, Qiu X, Spisak S, Nagy Z, et al
    A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
    Cancer Res. 2022 Aug 11. pii: 707656. doi: 10.1158/0008-5472.CAN-21-3186.
    >> Share

  79. WU C, Jarrett AM, Zhou Z, Elshafeey N, et al
    MRI-based digital models forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer.
    Cancer Res. 2022 Aug 1. pii: 707362. doi: 10.1158/0008-5472.CAN-22-1329.
    >> Share

    July 2022
  80. TIMPERI E, Gueguen P, Molgora M, Magagna I, et al
    Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer.
    Cancer Res. 2022 Jul 21. pii: 707127. doi: 10.1158/0008-5472.CAN-22-1427.
    >> Share

  81. CHEN F, Park SL, Wilkens LR, Wan P, et al
    Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study.
    Cancer Res. 2022 Jul 14. pii: 707009. doi: 10.1158/0008-5472.CAN-21-4461.
    >> Share

    June 2022
  82. KALRA R, Chen CH, Wang J, Salam AB, et al
    Poziotinib inhibits HER2 mutant-driven therapeutic resistance and multi-organ metastasis in breast cancer.
    Cancer Res. 2022 Jun 23. pii: 705013. doi: 10.1158/0008-5472.CAN-21-3106.
    >> Share

  83. CLARIDGE SE, Hopkins BD
    PI3King the Environment for Growth: PI3K Activation Drives Transcriptome Changes That Support Oncogenic Growth.
    Cancer Res. 2022;82:2216-2218.
    >> Share

  84. LADEWIG E, Michelini F, Jhaveri K, Castel P, et al
    The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation.
    Cancer Res. 2022;82:2269-2280.
    >> Share

  85. ZHANG Z, Golomb L, Meyerson M
    Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines.
    Cancer Res. 2022;82:2171-2184.
    >> Share

    May 2022
  86. KOPANJA D, Chand V, O'Brien EM, Mukhopadhyay NK, et al
    Transcriptional repression by FoxM1 suppresses tumor differentiation and promotes metastasis of breast cancer.
    Cancer Res. 2022 May 18. pii: 699021. doi: 10.1158/0008-5472.CAN-22-0410.
    >> Share

  87. WEI YT, Wang XR, Yan C, Huang F, et al
    Thymosin alpha-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis.
    Cancer Res. 2022;82:1991-2002.
    >> Share

  88. FATHERREE JP, Guarin JR, McGinn RA, Naber SP, et al
    Chemotherapy-Induced Collagen IV Drives Cancer Cell Motility through Activation of Src and Focal Adhesion Kinase.
    Cancer Res. 2022;82:2031-2044.
    >> Share

  89. MARCZYK M, Gunasekharan V, Casadevall D, Qing T, et al
    Comprehensive Analysis of Metabolic Isozyme Targets in Cancer.
    Cancer Res. 2022;82:1698-1711.
    >> Share

    April 2022
  90. RODRIGUEZ-TIRADO C, Kale N, Carlini MJ, Shrivastava N, et al
    NR2F1 is a barrier to dissemination of early stage breast cancer cells.
    Cancer Res. 2022 Apr 26. pii: 694636. doi: 10.1158/0008-5472.CAN-21-4145.
    >> Share

  91. SINGH S, Lee N, Pedroza DA, Bado IL, et al
    Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer.
    Cancer Res. 2022 Apr 20. pii: 694629. doi: 10.1158/0008-5472.CAN-21-3714.
    >> Share

  92. QUIROS-GONZALEZ I, Tomaszewski MR, Golinska MA, Brown E, et al
    Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models.
    Cancer Res. 2022;82:1658-1668.
    >> Share

  93. PELLEGRINO B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, et al
    Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    Cancer Res. 2022;82:1646-1657.
    >> Share

  94. WANG H, Xu H, Chen W, Cheng M, et al
    Rab13 sustains breast cancer stem cells by supporting tumor-stroma crosstalk.
    Cancer Res. 2022 Apr 8. pii: 694330. doi: 10.1158/0008-5472.CAN-21-4097.
    >> Share

  95. ELWAKEEL E, Bruggemann M, Wagih J, Lityagina O, et al
    Disruption of Prostaglandin E2 Signaling in Cancer-Associated Fibroblasts Limits Mammary Carcinoma Growth but Promotes Metastasis.
    Cancer Res. 2022;82:1380-1395.
    >> Share

  96. HONG Z, Liu T, Wan L, Fa P, et al
    Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy Efficacy.
    Cancer Res. 2022;82:1298-1312.
    >> Share

    March 2022
  97. SAMANTA D, Park Y, Andrabi SA, Shelton LM, et al
    Correction: PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis.
    Cancer Res. 2022;82:1153.
    >> Share

  98. WILSON Z, Odedra R, Wallez Y, Wijnhoven PWG, et al
    ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
    Cancer Res. 2022;82:1140-1152.
    >> Share

  99. GILKES DM, Chaturvedi P, Bajpai S, Wong CC, et al
    Editor's Note: Collagen Prolyl Hydroxylases Are Essential for Breast Cancer Metastasis.
    Cancer Res. 2022;82:943.
    >> Share

    February 2022
  100. BHATIA S, Kramer M, Russo S, Naik P, et al
    Patient-derived triple-negative breast cancer organoids provide robust model systems that recapitulate tumor-intrinsic characteristics.
    Cancer Res. 2022 Feb 18. pii: 681619. doi: 10.1158/0008-5472.CAN-21-2807.
    >> Share

  101. CHU W, Zhang X, Qi L, Fu Y, et al
    Correction: The EZH2-PHACTR2-AS1- Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer.
    Cancer Res. 2022;82:735.
    >> Share

  102. SCHEIDMANN MC, Castro-Giner F, Strittmatter K, Krol I, et al
    An In Vivo CRISPR Screen Identifies Stepwise Genetic Dependencies of Metastatic Progression.
    Cancer Res. 2022;82:681-694.
    >> Share

  103. LIAO C, Glodowski CR, Fan C, Liu J, et al
    Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers.
    Cancer Res. 2022;82:665-680.
    >> Share

  104. BOONEN RACM, Wiegant WW, Celosse N, Vroling B, et al
    Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk.
    Cancer Res. 2022;82:615-631.
    >> Share

  105. LI XQ, Zhang R, Lu H, Yue XM, et al
    Extracellular vesicle-packaged CDH11 and ITGA5 induce the premetastatic niche for bone colonization of breast cancer cells.
    Cancer Res. 2022 Feb 11. pii: 0008-5472.CAN-21-1331.
    >> Share

    January 2022
  106. LI Z, Wu Y, Yates ME, Tasdemir N, et al
    Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis.
    Cancer Res. 2022 Jan 25. pii: 0008-5472.CAN-21-2576.
    >> Share

  107. MAJORINI MT, Colombo MP, Lecis D
    Few, but efficient: the role of mast cells in breast cancer and other solid tumors.
    Cancer Res. 2022 Jan 19. pii: 0008-5472.CAN-21-3424.
    >> Share

  108. HAJ-SHOMALY J, Vorontsova A, Barenholz-Cohen T, Levi-Galibov O, et al
    T Cells Promote Metastasis by Regulating Extracellular Matrix Remodeling following Chemotherapy.
    Cancer Res. 2022;82:278-291.
    >> Share

  109. ZHU WJ, Chen X, Guo XY, Liu HT, et al
    Low glucose-induced overexpression of HOXC-AS3 promotes metabolic reprogramming of breast cancer.
    Cancer Res. 2022 Jan 14. pii: 0008-5472.CAN-21-1179.
    >> Share

    December 2021
  110. XU Y, Ren W, Li Q, Duan C, et al
    LncRNA Uc003xsl.1-mediated activation of the NF-kappaB/IL8 axis promotes progression of triple-negative breast cancer.
    Cancer Res. 2021 Dec 29. pii: 0008-5472.CAN-21-1446.
    >> Share

  111. BEETHAM H, Griffith BGC, Murina O, Loftus AE, et al
    Loss of Integrin-linked kinase sensitizes breast cancer to SRC inhibitors.
    Cancer Res. 2021 Dec 17. pii: 0008-5472.CAN-21-0373.
    >> Share

  112. OBA T, Kajihara R, Yokoi T, Repasky EA, et al
    Neoadjuvant In Situ Immunomodulation Enhances Systemic Antitumor Immunity against Highly Metastatic Tumors.
    Cancer Res. 2021;81:6183-6195.
    >> Share

  113. MOORE J, Ma L, Lazar A, Barcellos-Hoff MH, et al
    Mammary tumor-derived transplants as breast cancer models to evaluate tumor-immune interactions and therapeutic responses.
    Cancer Res. 2021 Dec 13. pii: 0008-5472.CAN-21-0253.
    >> Share

    November 2021
  114. CHOI SR, Hwang CY, Lee J, Cho KH, et al
    Network Analysis Identifies Regulators of Basal-Like Breast Cancer Reprogramming and Endocrine Therapy Vulnerability.
    Cancer Res. 2021 Nov 29. pii: 0008-5472.CAN-21-0621.
    >> Share

  115. YUAN H, Yan L, Wu M, Shang Y, et al
    Analysis of the estrogen receptor-associated lncRNA landscape identifies a role for ERLC1 in breast cancer progression.
    Cancer Res. 2021 Nov 22. pii: 0008-5472.CAN-21-1155.
    >> Share

  116. SUBRAMANIAN S, Daquinag AC, AghaAmiri S, Ghosh SC, et al
    Characterization of Peptides Targeting Metastatic Tumor Cells as Probes for Cancer Detection and Vehicles for Therapy Delivery.
    Cancer Res. 2021;81:5756-5764.
    >> Share

  117. JANJANAM J, Pano G, Wang R, Minden-Birkenmaier BA, et al
    Matricellular Protein WISP2 Is an Endogenous Inhibitor of Collagen Linearization and Cancer Metastasis.
    Cancer Res. 2021;81:5666-5677.
    >> Share

  118. XING F, Liu Y, Wu SY, Wu K, et al
    Correction: Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis.
    Cancer Res. 2021;81:5582.
    >> Share

  119. DAMODARAN S, Hortobagyi GN
    Estrogen Receptor: A Paradigm for Targeted Therapy.
    Cancer Res. 2021;81:5396-5398.
    >> Share

  120. GRISARU-TAL S, Dulberg S, Beck L, Zhang C, et al
    Metastasis-Entrained Eosinophils Enhance Lymphocyte-Mediated Antitumor Immunity.
    Cancer Res. 2021;81:5555-5571.
    >> Share

  121. TEMPS C, Lietha D, Webb ER, Li XF, et al
    A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability.
    Cancer Res. 2021;81:5438-5450.
    >> Share

  122. HINSHAW DC, Hanna A, Lama-Sherpa T, Metge B, et al
    Hedgehog Signaling Regulates Metabolism and Polarization of Mammary Tumor-Associated Macrophages.
    Cancer Res. 2021;81:5425-5437.
    >> Share

    October 2021
  123. PATEL A, Garcia-Closas M, Olshan AF, Perou CM, et al
    Gene level germline contributions to clinical risk of recurrence scores in Black and White breast cancer patients.
    Cancer Res. 2021 Oct 28. pii: 0008-5472.CAN-21-1207.
    >> Share

  124. DONE SJ, Kanwar N, Balde Z, Nair R, et al
    Heterogeneity of circulating tumor cell-associated genomic gains in breast cancer and its association with the host immune response.
    Cancer Res. 2021 Oct 28. pii: 0008-5472.CAN-21-1079.
    >> Share

  125. GOU X, Anurag M, Lei JT, Kim BJ, et al
    Transcriptional reprogramming differentiates active from inactive ESR1 fusions in endocrine therapy-refractory metastatic breast cancer.
    Cancer Res. 2021 Oct 28. pii: 0008-5472.CAN-21-1256.
    >> Share

  126. HUGGINS DN, LaRue RS, Wang Y, Knutson TP, et al
    Characterizing Macrophage Diversity in Metastasis-Bearing Lungs Reveals a Lipid-Associated Macrophage Subset.
    Cancer Res. 2021;81:5284-5295.
    >> Share

  127. WOITEK R, McLean MA, Ursprung S, Rueda OM, et al
    Hyperpolarized carbon-13 MRI for early response assessment of neoadjuvant chemotherapy in breast cancer patients.
    Cancer Res. 2021 Oct 8. pii: 0008-5472.CAN-21-1499.
    >> Share

    September 2021
  128. LIU C, Qiang J, Deng Q, Xia J, et al
    ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression.
    Cancer Res. 2021 Sep 27. pii: 0008-5472.CAN-21-1337.
    >> Share

  129. ZHAO X, Li J, Liu Z, Powers S, et al
    Combinatorial CRISPR/Cas9 Screening Reveals Epistatic Networks of Interacting Tumor Suppressor Genes and Therapeutic Targets in Human Breast Cancer.
    Cancer Res. 2021 Sep 24. pii: 0008-5472.CAN-21-2555.
    >> Share

  130. ANSARI KI, Bhan A, Saotome M, Tyagi A, et al
    Autocrine GMCSF Signaling Contributes to Growth of HER2(+) Breast Leptomeningeal Carcinomatosis.
    Cancer Res. 2021;81:4723-4735.
    >> Share

  131. FAURE C, Djerbi-Bouillie R, Domingot A, Bouzinba-Segard H, et al
    Allosteric inhibition of HER2 by Moesin-mimicking compounds targets HER2-positive cancers and brain metastases.
    Cancer Res. 2021 Sep 7. pii: 0008-5472.CAN-21-0162.
    >> Share

    August 2021
  132. PULEO J, Polyak K
    The MCF10 Model of Breast Tumor Progression.
    Cancer Res. 2021;81:4183-4185.
    >> Share

  133. APOSTOLIDI M, Vathiotis IA, Muthusamy V, Gaule P, et al
    Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes.
    Cancer Res. 2021;81:4346-4359.
    >> Share

    July 2021
  134. TAKAYAMA KI, Honma T, Suzuki T, Kondoh Y, et al
    Targeting Epigenetic and Posttranscriptional Gene Regulation by PSF Impairs Hormone Therapy-Refractory Cancer Growth.
    Cancer Res. 2021;81:3495-3508.
    >> Share

  135. STEINER MC, Marston JL, Iniguez LP, Bendall ML, et al
    Locus-Specific Characterization of Human Endogenous Retrovirus Expression in Prostate, Breast, and Colon Cancers.
    Cancer Res. 2021;81:3449-3460.
    >> Share

  136. CHOI H, Kwon J, Cho MS, Sun Y, et al
    Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon Response.
    Cancer Res. 2021;81:3607-3620.
    >> Share

  137. YOO KH, Tang JJ, Rashid MA, Cho CH, et al
    Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments.
    Cancer Res. 2021;81:3727-3737.
    >> Share

    June 2021
  138. BHAN A, Ansari KI, Chen MY, Jandial R, et al
    Inhibition of Jumonji Histone Demethylases Selectively Suppresses HER2(+) Breast Leptomeningeal Carcinomatosis Growth via Inhibition of GMCSF Expression.
    Cancer Res. 2021;81:3200-3214.
    >> Share

  139. ZHOU Q, Howard ME, Tu X, Zhu Q, et al
    Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining.
    Cancer Res. 2021;81:3333-3346.
    >> Share

    May 2021
  140. YANG B, Li X, Fu Y, Guo E, et al
    MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors.
    Cancer Res. 2021;81:2714-2729.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016